Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1(Currently Amended). A method of treating ~~diseases~~ a disease mediated by transglutaminase, comprising administering to a patient in need thereof an effective amount of a transglutaminase inhibitor selected from the group consisting of monodansyl cadaverine, cystamine, putrescine, a monoamine, a diamine, gamma-amino benzoic acid, N-benzyloxy carbonyl, 5-deazo-4-oxonorvaline p-nitrophenylester, glycine methyl ester, $CuSO_4$, and tolbutamide, wherein the disease is selected from the group consisting of Huntington's Disease, spinobulbar atrophy, spinocerebellar ataxia, Machado-Joseph disease, and dentatorubralpallidoluysian atrophy.

Claims 2-16 (Cancelled).

17(New). The method of claim 1, wherein the transglutaminase inhibitor is monodansyl cadaverine.

18(New). The method of claim 1, wherein the transglutaminase inhibitor is cystamine.

19(New). The method of claim 1, wherein the transglutaminase inhibitor is putrescine.

20(New). The method of claim 1, wherein the transglutaminase inhibitor is gamma-amino benzoic acid.

21(New). The method of claim 1, wherein the transglutaminase inhibitor is N-benzyloxy carbonyl.

22(New). The method of claim 1, wherein the transglutaminase inhibitor is 5-deazo-4-oxonorvaline p-nitrophenylester.

23(New). The method of claim 1, wherein the transglutaminase inhibitor is glycine methyl ester.

24(New). The method of claim 1, wherein the transglutaminase inhibitor is $CuSO_4$.

25(New). The method of claim 1, wherein the transglutaminase inhibitor is tolbutamide.

26(New). The method of claim 1, wherein the disease is Huntington's Disease.

27(New). The method of claim 1, wherein the disease is spinobulbar atrophy.

28(New). The method of claim 1, wherein the disease is spinocerebellar ataxia.

29(New). The method of claim 1, wherein the disease is Machado-Joseph disease.

30(New). The method of claim 1, wherein the disease is dentatorubralpallidoluysian atrophy.